Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Merck & Co., Inc.
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
April 01, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer
March 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
March 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer
March 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT
March 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation
March 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
March 17, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial
March 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility
March 15, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
February 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Shares Environmental, Social & Governance Priorities and Strategy
February 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces New Leadership for Human Health Business
February 16, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status
February 14, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities
February 14, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine
February 09, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States
February 08, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Guggenheim Oncology Conference 2022
February 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
February 03, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
January 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
January 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Second-Quarter 2022 Dividend
January 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides U.S. and Japan Regulatory Update for Gefapixant
January 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
January 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Frank Clyburn to Leave Merck
January 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
January 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
January 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
January 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
January 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.